[go: up one dir, main page]

WO2005053604A3 - Antibodies specific for cancer associated antigen sm5-1 and uses thereof - Google Patents

Antibodies specific for cancer associated antigen sm5-1 and uses thereof Download PDF

Info

Publication number
WO2005053604A3
WO2005053604A3 PCT/US2004/017855 US2004017855W WO2005053604A3 WO 2005053604 A3 WO2005053604 A3 WO 2005053604A3 US 2004017855 W US2004017855 W US 2004017855W WO 2005053604 A3 WO2005053604 A3 WO 2005053604A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies specific
associated antigen
cancer associated
antibodies
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/017855
Other languages
French (fr)
Other versions
WO2005053604A2 (en
Inventor
Jing Ma
Yajun Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomax Acquisition Corp
Original Assignee
Oncomax Acquisition Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2003101199264A external-priority patent/CN1279056C/en
Application filed by Oncomax Acquisition Corp filed Critical Oncomax Acquisition Corp
Priority to AU2004294893A priority Critical patent/AU2004294893A1/en
Priority to CA002528182A priority patent/CA2528182A1/en
Priority to JP2006533570A priority patent/JP2007535905A/en
Priority to EP04776307A priority patent/EP1631238A2/en
Publication of WO2005053604A2 publication Critical patent/WO2005053604A2/en
Priority to IL172242A priority patent/IL172242A0/en
Anticipated expiration legal-status Critical
Publication of WO2005053604A3 publication Critical patent/WO2005053604A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns antibodies which is specific for SM5-1 antigen expressed in melanoma, breast cancer and hepatocellular carcinoma, and polynucleotides encoding the antibodies. The invention further concerns use of such antibodies and/or polynucleotides in diagnosing and treating malignancies.
PCT/US2004/017855 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen sm5-1 and uses thereof Ceased WO2005053604A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004294893A AU2004294893A1 (en) 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CA002528182A CA2528182A1 (en) 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen sm5-1 and uses thereof
JP2006533570A JP2007535905A (en) 2003-06-06 2004-06-04 Specific antibody of cancer-associated antigen SM5-1 and use thereof
EP04776307A EP1631238A2 (en) 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen sm5-1 and uses thereof
IL172242A IL172242A0 (en) 2003-06-06 2005-11-29 Antibodies specific for cancer associated antigen sm5-1 and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN03129123.6 2003-06-06
CN03129123 2003-06-06
CNB2003101199264A CN1279056C (en) 2003-06-06 2003-11-25 Specific antibody of tumor-associated antigen SM5-1 and use thereof
CN2003101199264 2003-11-25
US10/722,849 2003-11-26
US10/722,849 US20050031617A1 (en) 2003-06-06 2003-11-26 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
TW092133571A TW200517122A (en) 2003-06-06 2003-11-28 Antibodies specific for cancer associated antigen SM5-1 and uses thereof
TW092133571 2003-11-28

Publications (2)

Publication Number Publication Date
WO2005053604A2 WO2005053604A2 (en) 2005-06-16
WO2005053604A3 true WO2005053604A3 (en) 2006-02-09

Family

ID=42331655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017855 Ceased WO2005053604A2 (en) 2003-06-06 2004-06-04 Antibodies specific for cancer associated antigen sm5-1 and uses thereof

Country Status (5)

Country Link
JP (1) JP2007535905A (en)
AU (1) AU2004294893A1 (en)
CA (1) CA2528182A1 (en)
IL (1) IL172242A0 (en)
WO (1) WO2005053604A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595387A (en) * 2005-08-11 2013-04-26 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
AR062065A1 (en) 2006-07-14 2008-10-15 Ac Immune Sa HUMANIZED ANTIBODY
HRP20140049T1 (en) * 2007-01-05 2014-02-28 University Of Zürich Anti-beta-amyloid antibody and uses thereof
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
RU2556816C1 (en) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Strain of cells of chinese hamster ovaries - producer of recombinant antibody against tumour necrosis factor alpha of human being
CN109627337B (en) * 2018-12-29 2023-07-21 上海复宏汉霖生物技术股份有限公司 anti-PRLR monoclonal antibody, and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REINKE S ET AL: "Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.", AMERICAN JOURNAL OF DERMATOLOGY., vol. 27, no. 5, 2005, pages 401 - 406, XP008058050 *
TREFZER U ET AL: "SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.", ARCH DERMATOL RES., vol. 292, 2000, pages 583 - 589, XP002993817 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
AU2004294893A1 (en) 2005-06-16
WO2005053604A2 (en) 2005-06-16
JP2007535905A (en) 2007-12-13
CA2528182A1 (en) 2005-06-16
IL172242A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2003008583A3 (en) Novel compositions and methods for cancer
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2005123993A8 (en) Phage microarray profiling of the humoral response to disease
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
MXPA05008794A (en) Glycorpotein antigen sima135 expressed in metastatic human tumor cells.
WO2003045230A3 (en) Novel compositions and methods for cancer
TW200517122A (en) Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
WO2003080808A3 (en) Novel compositions and methods in cancer
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172242

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2528182

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004776307

Country of ref document: EP

Ref document number: 2006533570

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004294893

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2622/KOLNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004294893

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004776307

Country of ref document: EP